Collateral Sensitivity Networks in ALK-positive Lung Cancer Reveals Dynamic Nature of Drug Resistance

<p>H3122 ALK-positive NSCLC cell line evolved, over 16 weeks, to resistance for: 4 ALK inhibitors (ceritinib, alectinib, lorlatinib, crizotinib), 3 HSP-90 inhibitors (ganetespib, IPI504, AUY922), paclitaxel, pemetrexed, and etoposide; collateral sensitivities analyzed.</p